查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947963

长效PrEP市场依产品类型、最终用户、给药方案及分销管道划分，全球预测（2026-2032年）

Long-acting PrEP Market by Product Type, End User, Administration Setting, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，长效 PrEP 市场价值将达到 4.5206 亿美元，到 2026 年将成长至 4.751 亿美元，复合年增长率为 4.76%，到 ​​2032 年将达到 6.2606 亿美元。

关键市场统计数据
基准年 2025 4.5206亿美元
预计年份：2026年 4.751亿美元
预测年份 2032 6.2606亿美元
复合年增长率 (%) 4.76%

透过将临床创新、专案准备和相关人员的决策因素连结起来，制定促进PrEP持续推广的策略框架。

长效暴露前预防（PrEP）正在重新定义爱滋病预防，它将预防模式从每日服药转变为医护人员定期提供的保护。这一转变得益于製剂、给药方式和服务提供模式的创新，这些创新优先考虑了药物的持久性、便利性和保密性。相关人员在评估专案实施、采购途径和病患偏好，需要一种将科学进步与实际应用结合的综合方法。

了解技术、分销、监管和支付方方面的变化如何重塑持续性暴露前预防的机会和途径。

长效暴露前预防（PrEP）药物的格局正经历一场变革，其影响​​远不止于临床疗效，也体现在生产地域、分销模式以及支付方期望等。注射和植入式技术的进步正推动讨论从概念验证转向实际应用，促进了成熟製药企业、生物技术创新者和公共卫生机构之间的合作。这些伙伴关係正优先考虑可扩展的生产流程和标准化的培训课程，以支持大规模推广。

评估2025年关税调整对供应链转移、采购流程重组以及为保障PrEP可持续取得而需资金筹措方案的影响。

2025年实施的定向关税可能会重塑长效PrEP产品的供应链决策和筹资策略。关税带来的成本压力将增加进口组件、成品注射剂和植入装置的到岸成本，促使采购机构和製造商重新评估筹资策略。为此，相关人员可能会探索近岸外包、区域製造伙伴关係和垂直整合等方式，以维持单位经济效益并确保可预测的供应。

透过产品、分销管道、最终用户、人口统计和管理环境等多维度细分，可以确定需求路径和营运优先顺序。

细分市场分析揭示了产品属性、供应链基础设施、终端用户画像、目标人口以及管理环境如何相互作用，从而影响需求趋势和营运要求。按产品类别划分，植入和注射剂会产生不同的临床工作流程和训练需求。植入分为可生物降解型和不可生物降解型，其植入和取出需要一定的技术能力；而肌肉注射或皮下注射剂则需要考虑低温运输管理和熟练的注射技术。因此，每种产品亚型都针对不同的医疗服务提供者能力和病患咨询重点。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和能力差异将影响监管法规的采纳、采购选择和扩张路径。

区域趋势将显着影响投资、监管快速通道和试点计画的开展地点。在美洲，完善的法规结构和积极的私营部门参与将促进新型疗法的快速商业化。同时，一旦成本和供应风险得到控制，一些国家可能会鼓励透过公共卫生计画进行大规模采购。因此，製造商可能会优先考虑在监管清晰且采购能力强的市场开展示范计划和与支付方的合作。

协作、生产策略和循证商业化如何决定企业的竞争地位并影响市场准入结果

长效PrEP领域的企业活动呈现出策略授权、共同开发契约和产能投资结合的特性。拥有全球分销网络的成熟製药公司正在建立伙伴关係，以确保供应的连续性，并加快在各种法规环境下的核准。生物技术创新者提供差异化的给药平台，而契约製造组织（CMO）在扩大生产规模以满足波动的需求方面发挥日益重要的作用。

采取切实可行的策略步骤，确保供应韧性、差异化供应，并协调资金筹措，以扩大公平获得长效暴露前预防药物的机会。

行业领导者应优先采取一系列协调一致的行动，将临床创新与永续的医疗资源获取策略相结合。首先，应透过多元化生产基地和选择区域合作伙伴来增强生产韧性，从而降低关税和物流波动带来的风险；同时，还应签订包含价格稳定条款和多年期合约的商业协议，以确保供应稳定并保障公共专案预算。

一种结合专家一手研究、监管和贸易分析以及情境规划的调查方法，旨在得出可靠且可操作的结论。

本研究采用混合方法进行综合分析，结合专家访谈、监理申报资料审查及文献分析，以多角度了解长效暴露前预防（PrEP）的现况。主要资料包括对临床研究人员、供应链专业人员、采购负责人和专案负责人的结构化访谈，以了解实际操作情况和新出现的风险。这些定性观点与监管申报资料、已发表的临床试验结果和产品附加檔进行交叉比对，以确保技术准确性。

综合证据表明，协调的生产、供应和资金筹措行动对于实现持续 PrEP 的公共卫生潜力至关重要。

越来越多的证据表明，在不久的将来，持续剂量暴露前预防（PrEP）将从有限的推广阶段过渡到广泛纳入预防方案，但这取决于生产者、支付者和实施者之间的协调行动。儘管技术进步降低了临床应用门槛，但生产在地化、劳动力发展和采购模式设计等营运方面的限制仍然是关键因素。透过策略性的生产选择、灵活的配送模式和创新的资金筹措筹措方式来解决这些限制，将决定持续剂量模式能否充分发挥其预防潜力。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的长效PrEP市场

  • 植入
    • 可生物降解
    • 不可生物降解
  • 注射
    • 肌肉内注射
    • 皮下注射

9. 按最终用户分類的长效PrEP市场

  • 医院
    • 私立医院
    • 公立医院
  • NGO
    • 国际非政府组织
    • 当地非政府组织
  • 私人诊所
    • 性健康诊所
    • 性行为感染传染病诊所
  • 公共卫生项目
    • 社区支持计划
    • 政府资助项目

10. 依给药途径分類的长效PrEP市场

  • 临床环境
    • 诊所
    • 医院
  • 在家里
    • 护理师提供的行政协助
    • 自我管理

11. 按分销管道分類的长效PrEP市场

  • 离线
  • 在线的

第十二章 长效PrEP市场：依地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

13. 按组别分類的长效PrEP市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国长效PrEP市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 美国长效PrEP市场

第十六章 中国长效PrEP市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Accord Healthcare Inc.
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Ltd.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Gilead Sciences, Inc.
  • Hetero Labs Limited
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • ViiV Healthcare Limited
Product Code: MRR-4F7A6D4FB6AD

The Long-acting PrEP Market was valued at USD 452.06 million in 2025 and is projected to grow to USD 475.10 million in 2026, with a CAGR of 4.76%, reaching USD 626.06 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 452.06 million
Estimated Year [2026] USD 475.10 million
Forecast Year [2032] USD 626.06 million
CAGR (%) 4.76%

Setting the strategic context for long-acting PrEP adoption by connecting clinical innovation with programmatic readiness and stakeholder decision levers

Long-acting pre-exposure prophylaxis (PrEP) is redefining HIV prevention by shifting the paradigm from daily adherence to periodic, provider-mediated protection. This transformation is driven by innovations in formulation, delivery modalities, and service delivery models that prioritize durability, convenience, and confidentiality. As stakeholders evaluate programmatic adoption, procurement pathways, and patient preferences, they require a synthesis that links scientific progress with pragmatic pathways to scale.

The clinical promise of long-acting PrEP has accelerated policy conversations and procurement planning across public and private sectors. Early adopters are confronting implementation complexity ranging from cold chain logistics for injectables to training needs for implant insertion and removal. Consequently, decision-makers must weigh clinical efficacy alongside health system readiness, reimbursement architecture, and community acceptability. Importantly, technology choice is not neutral: product attributes such as dosing interval, route of administration, and reversibility materially affect uptake across distinct populations and care settings.

This executive summary presents a cohesive narrative that bridges innovation and implementation. It synthesizes structural shifts in the competitive and policy landscape, evaluates tariff-driven headwinds relevant to 2025, delineates segmentation-based uptake drivers, highlights regional dynamics, and articulates company-level behaviors that will shape access over the coming years. The aim is to equip leaders with the contextual intelligence needed to craft resilient strategies that prioritize equity, sustainability, and measurable public health impact.

Understanding how technological, distributional, regulatory, and payer shifts are remapping the long-acting PrEP opportunity and implementation pathways

The landscape for long-acting PrEP is undergoing transformative shifts that extend beyond clinical efficacy to encompass manufacturing geography, distribution models, and payer expectations. Advances in injectable and implant technologies have moved the conversation from proof-of-concept to real-world implementation, catalyzing alliances between established pharmaceutical manufacturers, biotech innovators, and public health institutions. These partnerships prioritize scalable production processes and standardized training curricula to support wide-scale rollouts.

Concurrently, the distribution ecosystem is evolving. Traditional hospital-centric delivery is being complemented by community-based outreach and digitally enabled channels that increase convenience and reduce stigma. New administration settings are emerging, enabling a mix of clinic-based procedures and hybrid nurse-assisted or supervised home administration models. Payment models are also shifting, with payers exploring value-based procurement and bundled purchasing arrangements that link reimbursement to adherence outcomes and program performance metrics.

Another fundamental shift is the greater granularity in target population segmentation. Decision-makers now segment demand not only by risk group but also by age cohorts and behavioral patterns, recognizing that adolescents, heterosexual adults, and men who have sex with men will require differentiated messaging, dosing intervals, and service designs. This segmentation drives differentiated commercial strategies and influences which product attributes are prioritized in procurement discussions.

Finally, regulatory and ethical considerations are ascending in importance. As longer-acting modalities extend protection windows, regulators and ethics boards are focusing on informed consent, reversibility, and adolescent access pathways. Together, these shifts mean that successful market entrants will couple clinical differentiation with operational excellence and sensitive community engagement strategies to deliver measurable prevention gains.

Evaluating how 2025 tariff shifts drive supply chain relocation, procurement reengineering, and financing solutions to protect access to long-acting PrEP

The introduction of targeted tariffs in 2025 has the potential to reshape supply chain decisions and procurement strategies for long-acting PrEP products. Tariff-induced cost pressure can increase landed costs for imported components, finished injectables, and implant devices, prompting procurement authorities and manufacturers to reassess sourcing strategies. In response, stakeholders are likely to explore nearshoring, regional manufacturing partnerships, and vertical integration to preserve unit economics and maintain predictable supply.

As a consequence, manufacturers with geographically diversified production footprints can mitigate exposure to tariff volatility by shifting volume between sites or by qualifying alternative component suppliers. Procurement agencies may respond by prioritizing suppliers with local assembly capabilities or by awarding multi-year contracts that include duties and tariff contingencies. This dynamic can advantage players who already have established manufacturing capacity in tariff-exempt jurisdictions or who can demonstrate the ability to localize critical stages of production.

Tariffs also create downstream effects on access and equity. Elevated import costs can constrain public program budgets, compelling health ministries and donors to make trade-offs between coverage breadth and product choice. In turn, this may delay rollouts in resource-constrained settings or incentivize selection of lower-cost modalities even when clinical preferences point to longer-acting options. To manage these tensions, procurement strategies will need to incorporate scenario planning that models tariff pass-through, demand smoothing mechanisms, and potential donor bridging funds.

Importantly, tariffs spur innovation in commercial contracting and financing. Stakeholders may adopt hedging mechanisms, long-term supplier agreements with price-stabilization clauses, or pooled regional procurement platforms that dilute the impact of duties across larger volumes. By proactively aligning manufacturing footprints with trade policy realities and by negotiating supplier commitments that address tariff risk, health systems and private payers can protect access while maintaining fiscal discipline.

How multi-dimensional segmentation by product, distribution, end user, demographics, and administration setting determines demand pathways and operational priorities

Segmentation analysis reveals how product characteristics, delivery infrastructure, end-user profiles, target demographics, and administration settings interact to shape demand trajectories and operational requirements. Product-wise differentiation between implant and injectable options creates distinct clinical workflows and training needs; implants, split into biodegradable and non-biodegradable types, require procedural competency for insertion and removal while injectables, delivered via intramuscular or subcutaneous routes, demand cold chain considerations and skilled administration. Each product subtype thus maps to different provider competencies and patient counseling priorities.

Distribution channel segmentation further clarifies where uptake will concentrate. Community health centers, whether fixed clinics or mobile clinics, enable decentralized access and are critical for reaching underserved populations. Hospital pharmacies, spanning private and public institutions, support integrated care pathways and are well-positioned for higher-acuity patients or those requiring concurrent clinical services. Certified online pharmacies can extend reach for prescription renewals and adherence support, whereas retail pharmacies, including chain and independent outlets, can facilitate walk-in access and reinforce continuity with primary care providers. These channel distinctions influence stock management, training cadence, and inventory turn-over policies.

End-user segmentation underscores diverse procurement and engagement models. Hospitals, both private and public, often centralize purchasing and can implement standardized protocols, while NGOs, whether international or local, drive targeted outreach and may secure donor-funded supply lines. Private clinics specializing in sexual health and STD services focus on patient experience and confidentiality, and public health programs-ranging from community outreach initiatives to government-funded schemes-are pivotal for equitable scale-up. Aligning product packaging, dosing schedules, and counseling materials to these end-user contexts increases acceptability and reduces service friction.

Target population segmentation-adolescents split into 15 to 19 and 20 to 24 cohorts, heterosexual adults divided into 25 to 49 and 50 plus brackets, and men who have sex with men categorized as adult MSM and young MSM-highlights the need for age-sensitive consent policies, differentiated communication channels, and tailored adherence supports. Adolescents may benefit from school-linked or youth-friendly services and flexible dosing schedules, whereas older adults may prefer clinic-based administration and long interval dosing. MSM populations often require stigma-reducing service environments and peer-led education to maximize uptake.

Administration setting segmentation between clinical settings (clinic and hospital) and home-based options (nurse-assisted administration and self-administration) reflects a continuum of care that balances medical oversight with convenience. Clinical settings provide safe environments for implants and complex injections, while home-based models can increase retention and reduce clinic burden when supported by nurse visits or validated self-administration protocols. Each administration pathway imposes different documentation, adverse-event monitoring, and supply chain requirements, demanding tailored protocols to safeguard quality and patient safety.

Regional dynamics and capacity differences in the Americas, EMEA, and Asia-Pacific that will shape regulatory uptake, procurement choices, and scale pathways

Regional dynamics materially influence where investments, regulatory fast-tracks, and programmatic pilots will emerge. In the Americas, established regulatory frameworks and robust private sector participation enable faster commercialization of novel modalities, while public health programs in selected countries can drive large-volume procurement once cost and supply are de-risked. Consequently, manufacturers may prioritize demonstration projects and payer engagements in markets that combine regulatory clarity with procurement capacity.

In Europe, the Middle East & Africa, heterogeneity is pronounced: some markets feature strong payer systems and advanced clinical adoption pathways, while others face constrained budgets and more centralized procurement processes. Donor-funded programs and multilateral procurement mechanisms remain crucial in many parts of Africa, and successful scale-up there will depend on aligning product affordability with service delivery innovations that reach communities beyond urban centers. The Middle East presents distinct regulatory and cultural considerations that require tailored engagement strategies and sensitive communication.

Asia-Pacific encompasses both high-capacity health systems that can integrate long-acting modalities rapidly and lower-resource settings that will depend on regional manufacturing and pooled procurement to drive sustainable access. The region's manufacturing capabilities, particularly in certain economies, offer opportunities for strategic partnerships that localize production and reduce exposure to trade disruptions. Across all regions, community engagement, regulatory harmonization efforts, and investments in workforce training will determine the pace at which long-acting PrEP becomes a routine component of prevention portfolios.

How collaborations, manufacturing strategies, and evidence-driven commercialization define company competitiveness and influence access outcomes

Company behavior in the long-acting PrEP space is characterized by a mix of strategic licensing, co-development agreements, and investments in manufacturing capacity. Incumbent pharmaceutical firms with global distribution networks are engaging in partnerships to accelerate registration across diverse regulatory environments while protecting supply continuity. Biotech innovators contribute differentiated delivery platforms, and contract manufacturing organizations play an increasingly prominent role in scaling production to meet variable demand.

Strategic moves include prioritizing clinical evidence generation that demonstrates not only efficacy but also safety across broader demographic cohorts, and investing in post-marketing surveillance systems to monitor real-world outcomes. Companies are also experimenting with pricing frameworks that balance sustainable margins with program affordability, including differential pricing across income contexts and outcome-linked contracting in some private markets. Portfolio diversification-maintaining both implant and injectable candidates-allows companies to hedge clinical and commercial risk while catering to distinct patient preferences and health system constraints.

Manufacturing and supply chain decisions are central to competitive positioning. Firms that can localize final assembly or establish regional fill-finish capacity are better insulated against trade policy shocks and can support public sector procurement requirements for local content. Additionally, companies that invest in training programs for clinicians and community health workers create durable adoption advantages by reducing implementation friction. Finally, transparent engagement with civil society and advocacy groups improves social license to operate and enhances demand generation, particularly among populations that have historically been marginalized in prevention efforts.

Practical strategic steps for leaders to secure supply resilience, enable differentiated delivery, and align financing to expand equitable access to long-acting PrEP

Industry leaders should prioritize a set of coordinated actions that align clinical innovation with durable access strategies. First, invest in manufacturing resilience by diversifying production footprints and qualifying regional partners to reduce exposure to tariff and logistics volatility. Pair that with commercial contracts that include price-stabilization clauses and multi-year commitments to enable predictable supply and to protect public program budgets.

Second, integrate service delivery innovation into product planning by designing administration-friendly formats and by resourcing training programs for clinicians, nurses, and community health workers. Coupled with this, develop differentiated engagement strategies for adolescents, heterosexual adults, and MSM cohorts that address consent pathways, stigma, and confidentiality concerns to improve uptake and retention.

Third, collaborate proactively with payers, procurement agencies, and donors to structure financing mechanisms that support equitable access. These mechanisms can include tiered pricing, pooled procurement arrangements, and outcome-linked reimbursement that ties payment to adherence or prevention milestones. Leaders should also sponsor implementation research and public-private demonstration projects to generate context-specific evidence that accelerates policy adoption.

Finally, adopt transparent communication and community partnership approaches that involve local NGOs, patient advocates, and clinical networks in co-designing rollout plans. This builds trust, ensures cultural sensitivity, and increases the likelihood of sustained program success. By operationalizing these recommendations, industry players can scale responsibly while maintaining commercial viability and advancing public health goals.

Methodological approach combining primary expert insights, regulatory and trade analysis, and scenario planning to underpin robust and actionable conclusions

This research synthesis draws on a mixed-methods approach that integrates primary expert interviews, regulatory dossier reviews, and secondary literature analysis to build a multidimensional understanding of the long-acting PrEP landscape. Primary inputs include structured interviews with clinical investigators, supply chain specialists, procurement officers, and program implementers to capture operational realities and emergent risks. These qualitative perspectives are triangulated with regulatory filings, publicly disclosed clinical trial results, and product monographs to ensure technical accuracy.

The analysis also incorporates a cross-jurisdictional review of trade policy developments relevant to 2025, examining tariff schedules, preferential trade agreements, and local content requirements that influence manufacturing and procurement decisions. Scenario planning techniques were used to model supply chain responses to tariff shocks, assessing likely shifts in sourcing, price pass-through, and procurement behavior under alternative policy futures.

Segmentation analysis was developed by mapping product attributes to distribution channels, end-user archetypes, target populations, and administration settings, thereby identifying friction points and adoption enablers across the value chain. Regional insights were derived from country-level policy reviews and stakeholder consultations to surface differences in regulatory pathways, procurement modalities, and health system capacity. Wherever possible, findings were validated through peer review with subject-matter experts to ensure robustness and to mitigate bias.

Synthesis of evidence showing that coordinated manufacturing, delivery, and financing actions are essential to realize the public health promise of long-acting PrEP

The accumulated evidence points to a near-term era where long-acting PrEP moves from constrained adoption to broader integration within prevention portfolios, contingent on coordinated action across manufacturers, payers, and implementers. Technological advances have lowered clinical barriers, but operational constraints-manufacturing localization, workforce training, and procurement design-remain decisive factors. Addressing these constraints through strategic manufacturing choices, responsive distribution models, and financing innovations will determine whether long-acting modalities achieve their prevention potential.

Equitable access will hinge on the ability of stakeholders to synchronize product availability with culturally competent service delivery. This requires aligning product portfolios to population needs, investing in decentralized distribution, and forging partnerships that place community voices at the center of rollout strategies. When these elements come together, long-acting PrEP can deliver sustained reductions in HIV incidence while preserving patient autonomy and reducing stigma.

In sum, the path to scale is navigable but requires deliberate, evidence-based choices. Organizations that act early to mitigate tariff risk, to invest in workforce capacity, and to co-design services with end users will capture both public health impact and commercial advantage. The coming years will reward those who balance scientific rigor with pragmatic implementation planning.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Long-acting PrEP Market, by Product Type

  • 8.1. Implant
    • 8.1.1. Biodegradable
    • 8.1.2. Non-Biodegradable
  • 8.2. Injectable
    • 8.2.1. Intramuscular
    • 8.2.2. Subcutaneous

9. Long-acting PrEP Market, by End User

  • 9.1. Hospitals
    • 9.1.1. Private Hospitals
    • 9.1.2. Public Hospitals
  • 9.2. NGOs
    • 9.2.1. International NGOs
    • 9.2.2. Local NGOs
  • 9.3. Private Clinics
    • 9.3.1. Sexual Health Clinics
    • 9.3.2. STD Clinics
  • 9.4. Public Health Programs
    • 9.4.1. Community Outreach Programs
    • 9.4.2. Government Funded Programs

10. Long-acting PrEP Market, by Administration Setting

  • 10.1. Clinical Setting
    • 10.1.1. Clinic
    • 10.1.2. Hospital
  • 10.2. Home Based
    • 10.2.1. Nurse Assisted Administration
    • 10.2.2. Self Administration

11. Long-acting PrEP Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Long-acting PrEP Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Long-acting PrEP Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Long-acting PrEP Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Long-acting PrEP Market

16. China Long-acting PrEP Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Accord Healthcare Inc.
  • 17.6. Amneal Pharmaceuticals, Inc.
  • 17.7. Aurobindo Pharma Ltd.
  • 17.8. Cipla Ltd.
  • 17.9. Dr. Reddy's Laboratories Ltd.
  • 17.10. Gilead Sciences, Inc.
  • 17.11. Hetero Labs Limited
  • 17.12. Lupin Limited
  • 17.13. Merck & Co., Inc.
  • 17.14. Mylan N.V.
  • 17.15. Sun Pharmaceutical Industries Ltd.
  • 17.16. Teva Pharmaceutical Industries Ltd.
  • 17.17. Viatris Inc.
  • 17.18. ViiV Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL LONG-ACTING PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LONG-ACTING PREP MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LONG-ACTING PREP MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LONG-ACTING PREP MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LONG-ACTING PREP MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LONG-ACTING PREP MARKET SIZE, BY ADMINISTRATION SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LONG-ACTING PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LONG-ACTING PREP MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LONG-ACTING PREP MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LONG-ACTING PREP MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES LONG-ACTING PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA LONG-ACTING PREP MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LONG-ACTING PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LONG-ACTING PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LONG-ACTING PREP MARKET SIZE, BY IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LONG-ACTING PREP MARKET SIZE, BY IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LONG-ACTING PREP MARKET SIZE, BY IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LONG-ACTING PREP MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LONG-ACTING PREP MARKET SIZE, BY BIODEGRADABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LONG-ACTING PREP MARKET SIZE, BY BIODEGRADABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LONG-ACTING PREP MARKET SIZE, BY BIODEGRADABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LONG-ACTING PREP MARKET SIZE, BY NON-BIODEGRADABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LONG-ACTING PREP MARKET SIZE, BY NON-BIODEGRADABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LONG-ACTING PREP MARKET SIZE, BY NON-BIODEGRADABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LONG-ACTING PREP MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LONG-ACTING PREP MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LONG-ACTING PREP MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LONG-ACTING PREP MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LONG-ACTING PREP MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LONG-ACTING PREP MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LONG-ACTING PREP MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LONG-ACTING PREP MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LONG-ACTING PREP MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LONG-ACTING PREP MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LONG-ACTING PREP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LONG-ACTING PREP MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LONG-ACTING PREP MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LONG-ACTING PREP MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LONG-ACTING PREP MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LONG-ACTING PREP MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LONG-ACTING PREP MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LONG-ACTING PREP MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LONG-ACTING PREP MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LONG-ACTING PREP MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LONG-ACTING PREP MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LONG-ACTING PREP MARKET SIZE, BY NGOS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LONG-ACTING PREP MARKET SIZE, BY NGOS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LONG-ACTING PREP MARKET SIZE, BY NGOS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LONG-ACTING PREP MARKET SIZE, BY NGOS, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LONG-ACTING PREP MARKET SIZE, BY INTERNATIONAL NGOS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LONG-ACTING PREP MARKET SIZE, BY INTERNATIONAL NGOS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LONG-ACTING PREP MARKET SIZE, BY INTERNATIONAL NGOS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LONG-ACTING PREP MARKET SIZE, BY LOCAL NGOS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LONG-ACTING PREP MARKET SIZE, BY LOCAL NGOS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LONG-ACTING PREP MARKET SIZE, BY LOCAL NGOS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LONG-ACTING PREP MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LONG-ACTING PREP MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LONG-ACTING PREP MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LONG-ACTING PREP MARKET SIZE, BY PRIVATE CLINICS, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LONG-ACTING PREP MARKET SIZE, BY SEXUAL HEALTH CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LONG-ACTING PREP MARKET SIZE, BY SEXUAL HEALTH CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LONG-ACTING PREP MARKET SIZE, BY SEXUAL HEALTH CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LONG-ACTING PREP MARKET SIZE, BY STD CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LONG-ACTING PREP MARKET SIZE, BY STD CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LONG-ACTING PREP MARKET SIZE, BY STD CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LONG-ACTING PREP MARKET SIZE, BY PUBLIC HEALTH PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LONG-ACTING PREP MARKET SIZE, BY PUBLIC HEALTH PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LONG-ACTING PREP MARKET SIZE, BY PUBLIC HEALTH PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LONG-ACTING PREP MARKET SIZE, BY PUBLIC HEALTH PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LONG-ACTING PREP MARKET SIZE, BY COMMUNITY OUTREACH PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LONG-ACTING PREP MARKET SIZE, BY COMMUNITY OUTREACH PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LONG-ACTING PREP MARKET SIZE, BY COMMUNITY OUTREACH PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LONG-ACTING PREP MARKET SIZE, BY GOVERNMENT FUNDED PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LONG-ACTING PREP MARKET SIZE, BY GOVERNMENT FUNDED PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LONG-ACTING PREP MARKET SIZE, BY GOVERNMENT FUNDED PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LONG-ACTING PREP MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LONG-ACTING PREP MARKET SIZE, BY CLINICAL SETTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LONG-ACTING PREP MARKET SIZE, BY CLINICAL SETTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LONG-ACTING PREP MARKET SIZE, BY CLINICAL SETTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LONG-ACTING PREP MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LONG-ACTING PREP MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LONG-ACTING PREP MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LONG-ACTING PREP MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LONG-ACTING PREP MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LONG-ACTING PREP MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LONG-ACTING PREP MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LONG-ACTING PREP MARKET SIZE, BY HOME BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LONG-ACTING PREP MARKET SIZE, BY HOME BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LONG-ACTING PREP MARKET SIZE, BY HOME BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LONG-ACTING PREP MARKET SIZE, BY HOME BASED, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LONG-ACTING PREP MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LONG-ACTING PREP MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LONG-ACTING PREP MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LONG-ACTING PREP MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LONG-ACTING PREP MARKET SIZE, BY SELF ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LONG-ACTING PREP MARKET SIZE, BY SELF ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL LONG-ACTING PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL LONG-ACTING PREP MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL LONG-ACTING PREP MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL LONG-ACTING PREP MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL LONG-ACTING PREP MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL LONG-ACTING PREP MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL LONG-ACTING PREP MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL LONG-ACTING PREP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS LONG-ACTING PREP MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS LONG-ACTING PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS LONG-ACTING PREP MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS LONG-ACTING PREP MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS LONG-ACTING PREP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS LONG-ACTING PREP MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS LONG-ACTING PREP MARKET SIZE, BY NGOS, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS LONG-ACTING PREP MARKET SIZE, BY PRIVATE CLINICS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS LONG-ACTING PREP MARKET SIZE, BY PUBLIC HEALTH PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS LONG-ACTING PREP MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS LONG-ACTING PREP MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS LONG-ACTING PREP MARKET SIZE, BY HOME BASED, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS LONG-ACTING PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA LONG-ACTING PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA LONG-ACTING PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA LONG-ACTING PREP MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA LONG-ACTING PREP MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA LONG-ACTING PREP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA LONG-ACTING PREP MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA LONG-ACTING PREP MARKET SIZE, BY NGOS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA LONG-ACTING PREP MARKET SIZE, BY PRIVATE CLINICS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA LONG-ACTING PREP MARKET SIZE, BY PUBLIC HEALTH PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA LONG-ACTING PREP MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA LONG-ACTING PREP MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA LONG-ACTING PREP MARKET SIZE, BY HOME BASED, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA LONG-ACTING PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA LONG-ACTING PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA LONG-ACTING PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA LONG-ACTING PREP MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA LONG-ACTING PREP MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA LONG-ACTING PREP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA LONG-ACTING PREP MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA LONG-ACTING PREP MARKET SIZE, BY NGOS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA LONG-ACTING PREP MARKET SIZE, BY PRIVATE CLINICS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA LONG-ACTING PREP MARKET SIZE, BY PUBLIC HEALTH PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA LONG-ACTING PREP MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA LONG-ACTING PREP MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA LONG-ACTING PREP MARKET SIZE, BY HOME BASED, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA LONG-ACTING PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING PREP MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING PREP MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING PREP MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING PREP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING PREP MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING PREP MARKET SIZE, BY NGOS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING PREP MARKET SIZE, BY PRIVATE CLINICS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING PREP MARKET SIZE, BY PUBLIC HEALTH PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING PREP MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING PREP MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING PREP MARKET SIZE, BY HOME BASED, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE LONG-ACTING PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE LONG-ACTING PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE LONG-ACTING PREP MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE LONG-ACTING PREP MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE LONG-ACTING PREP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE LONG-ACTING PREP MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE LONG-ACTING PREP MARKET SIZE, BY NGOS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE LONG-ACTING PREP MARKET SIZE, BY PRIVATE CLINICS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE LONG-ACTING PREP MARKET SIZE, BY PUBLIC HEALTH PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE LONG-ACTING PREP MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE LONG-ACTING PREP MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE LONG-ACTING PREP MARKET SIZE, BY HOME BASED, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE LONG-ACTING PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST LONG-ACTING PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST LONG-ACTING PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST LONG-ACTING PREP MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST LONG-ACTING PREP MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST LONG-ACTING PREP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST LONG-ACTING PREP MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST LONG-ACTING PREP MARKET SIZE, BY NGOS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST LONG-ACTING PREP MARKET SIZE, BY PRIVATE CLINICS, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST LONG-ACTING PREP MARKET SIZE, BY PUBLIC HEALTH PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST LONG-ACTING PREP MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST LONG-ACTING PREP MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST LONG-ACTING PREP MARKET SIZE, BY HOME BASED, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST LONG-ACTING PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA LONG-ACTING PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA LONG-ACTING PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA LONG-ACTING PREP MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA LONG-ACTING PREP MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA LONG-ACTING PREP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA LONG-ACTING PREP MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA LONG-ACTING PREP MARKET SIZE, BY NGOS, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA LONG-ACTING PREP MARKET SIZE, BY PRIVATE CLINICS, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA LONG-ACTING PREP MARKET SIZE, BY PUBLIC HEALTH PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA LONG-ACTING PREP MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA LONG-ACTING PREP MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA LONG-ACTING PREP MARKET SIZE, BY HOME BASED, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA LONG-ACTING PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC LONG-ACTING PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC LONG-ACTING PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC LONG-ACTING PREP MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC LONG-ACTING PREP MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC LONG-ACTING PREP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC LONG-ACTING PREP MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC LONG-ACTING PREP MARKET SIZE, BY NGOS, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC LONG-ACTING PREP MARKET SIZE, BY PRIVATE CLINICS, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC LONG-ACTING PREP MARKET SIZE, BY PUBLIC HEALTH PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC LONG-ACTING PREP MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC LONG-ACTING PREP MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC LONG-ACTING PREP MARKET SIZE, BY HOME BASED, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC LONG-ACTING PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL LONG-ACTING PREP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN LONG-ACTING PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN LONG-ACTING PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN LONG-ACTING PREP MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN LONG-ACTING PREP MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN LONG-ACTING PREP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN LONG-ACTING PREP MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN LONG-ACTING PREP MARKET SIZE, BY NGOS, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN LONG-ACTING PREP MARKET SIZE, BY PRIVATE CLINICS, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN LONG-ACTING PREP MARKET SIZE, BY PUBLIC HEALTH PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN LONG-ACTING PREP MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN LONG-ACTING PREP MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN LONG-ACTING PREP MARKET SIZE, BY HOME BASED, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN LONG-ACTING PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. GCC LONG-ACTING PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. GCC LONG-ACTING PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. GCC LONG-ACTING PREP MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 214. GCC LONG-ACTING PREP MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 215. GCC LONG-ACTING PREP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GCC LONG-ACTING PREP MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 217. GCC LONG-ACTING PREP MARKET SIZE, BY NGOS, 2018-2032 (USD MILLION)
  • TABLE 218. GCC LONG-ACTING PREP MARKET SIZE, BY PRIVATE CLINICS, 2018-2032 (USD MILLION)
  • TABLE 219. GCC LONG-ACTING PREP MARKET SIZE, BY PUBLIC HEALTH PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC LONG-ACTING PREP MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 221. GCC LONG-ACTING PREP MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 222. GCC LONG-ACTING PREP MARKET SIZE, BY HOME BASED, 2018-2032 (USD MILLION)
  • TABLE 223. GCC LONG-ACTING PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION LONG-ACTING PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION LONG-ACTING PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION LONG-ACTING PREP MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION LONG-ACTING PREP MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION LONG-ACTING PREP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION LONG-ACTING PREP MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION LONG-ACTING PREP MARKET SIZE, BY NGOS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION LONG-ACTING PREP MARKET SIZE, BY PRIVATE CLINICS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION LONG-ACTING PREP MARKET SIZE, BY PUBLIC HEALTH PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION LONG-ACTING PREP MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION LONG-ACTING PREP MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION LONG-ACTING PREP MARKET SIZE, BY HOME BASED, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION LONG-ACTING PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS LONG-ACTING PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS LONG-ACTING PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS LONG-ACTING PREP MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS LONG-ACTING PREP MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS LONG-ACTING PREP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS LONG-ACTING PREP MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS LONG-ACTING PREP MARKET SIZE, BY NGOS, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS LONG-ACTING PREP MARKET SIZE, BY PRIVATE CLINICS, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS LONG-ACTING PREP MARKET SIZE, BY PUBLIC HEALTH PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS LONG-ACTING PREP MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS LONG-ACTING PREP MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS LONG-ACTING PREP MARKET SIZE, BY HOME BASED, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS LONG-ACTING PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. G7 LONG-ACTING PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. G7 LONG-ACTING PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. G7 LONG-ACTING PREP MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 253. G7 LONG-ACTING PREP MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 254. G7 LONG-ACTING PREP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. G7 LONG-ACTING PREP MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 256. G7 LONG-ACTING PREP MARKET SIZE, BY NGOS, 2018-2032 (USD MILLION)
  • TABLE 257. G7 LONG-ACTING PREP MARKET SIZE, BY PRIVATE CLINICS, 2018-2032 (USD MILLION)
  • TABLE 258. G7 LONG-ACTING PREP MARKET SIZE, BY PUBLIC HEALTH PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 259. G7 LONG-ACTING PREP MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 260. G7 LONG-ACTING PREP MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 261. G7 LONG-ACTING PREP MARKET SIZE, BY HOME BASED, 2018-2032 (USD MILLION)
  • TABLE 262. G7 LONG-ACTING PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. NATO LONG-ACTING PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. NATO LONG-ACTING PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. NATO LONG-ACTING PREP MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 266. NATO LONG-ACTING PREP MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 267. NATO LONG-ACTING PREP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. NATO LONG-ACTING PREP MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 269. NATO LONG-ACTING PREP MARKET SIZE, BY NGOS, 2018-2032 (USD MILLION)
  • TABLE 270. NATO LONG-ACTING PREP MARKET SIZE, BY PRIVATE CLINICS, 2018-2032 (USD MILLION)
  • TABLE 271. NATO LONG-ACTING PREP MARKET SIZE, BY PUBLIC HEALTH PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 272. NATO LONG-ACTING PREP MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 273. NATO LONG-ACTING PREP MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 274. NATO LONG-ACTING PREP MARKET SIZE, BY HOME BASED, 2018-2032 (USD MILLION)
  • TABLE 275. NATO LONG-ACTING PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL LONG-ACTING PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES LONG-ACTING PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES LONG-ACTING PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES LONG-ACTING PREP MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES LONG-ACTING PREP MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES LONG-ACTING PREP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES LONG-ACTING PREP MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES LONG-ACTING PREP MARKET SIZE, BY NGOS, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES LONG-ACTING PREP MARKET SIZE, BY PRIVATE CLINICS, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES LONG-ACTING PREP MARKET SIZE, BY PUBLIC HEALTH PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES LONG-ACTING PREP MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES LONG-ACTING PREP MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES LONG-ACTING PREP MARKET SIZE, BY HOME BASED, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES LONG-ACTING PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA LONG-ACTING PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA LONG-ACTING PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA LONG-ACTING PREP MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA LONG-ACTING PREP MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA LONG-ACTING PREP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA LONG-ACTING PREP MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA LONG-ACTING PREP MARKET SIZE, BY NGOS, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA LONG-ACTING PREP MARKET SIZE, BY PRIVATE CLINICS, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA LONG-ACTING PREP MARKET SIZE, BY PUBLIC HEALTH PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA LONG-ACTING PREP MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA LONG-ACTING PREP MARKET SIZE, BY CLINICAL SETTING, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA LONG-ACTING PREP MARKET SIZE, BY HOME BASED, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA LONG-ACTING PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)